Get alerts when GUTS reports next quarter
Set up alerts — freeFractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.
See GUTS alongside your other holdings
Add to your portfolio — freeTrack Fractyl Health, Inc. Common Stock in your portfolio with real-time analytics, dividend tracking, and more.
View GUTS Analysis